Cancer research

News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer.  As February 4 is World Cancer Day, this week’s update focuses on developments in the field of oncology. Drugs for lung cancer, lymphoma and breast cancer have received regulatory approvals, an investment boost will allow the development of a novel approach to treating tumours, and […]

The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer has been approved in the US.  The Food and Drug Administration (FDA) has approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with […]

Bryan Oronsky, Chief Development Officer at EpicentRx, discucsses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. Introduction The term “dilettante”, at least in English, connotes a sloppy bungler, a smatterer, a second rater, unskilled and unserious, lacking breadth and depth, and someone to whom the pejorative label, […]

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS.  Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who […]

DDW Editor Reece Armstrong looks into recent research which may explain why cancers can become more aggressive. Researchers in London and Milan may have discovered why cancers can become more aggressive without relying only on DNA mutations. A lot of research to do with cancer has focused on the way cancers can occur and evolve […]

Enhertu has been approved in the EU as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer.  The drug is approved as monotherapy for adult patients who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.  Enhertu is a […]

DDW Editor Reece Armstrong explores recent research looking into why cancer cells are so effective at avoiding the body’s immune system. Scientists may have discovered clues to why cancer cells can avoid the body’s immune system in a study conducted by researchers at Harvard Medical School. For years now, scientists have been trying to understand […]

Cancer cells can shrink or super-size themselves to survive drug treatment or other challenges within their environment, researchers have discovered.  Scientists at The Institute of Cancer Research, London, combined biochemical profiling technologies with mathematical analyses to reveal how genetic changes lead to differences in the size of cancer cells – and how these changes could […]

DDW Editor Reece Armstrong covers news of a drug which could be used to treat triple-negative breast cancer with less side effects. A less toxic treatment for a specific type of breast cancer may be on the horizon due to a new drug developed by a team at the University of Arizona.  The team from the […]

CARsgen Therapeutics and Huadong Medicine (Hangzhou) will collaborate on the commercialisation of CARsgen’s BCMA CAR-T product CT053 in mainland China.  CT053 (zevorcabtagene autoleucel, Zevor-cel) is CARsgen’s lead drug candidate and an autologous CAR T-cell product treating relapsed/refractory multiple myeloma (R/R MM).  Dr Zonghai Li, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer […]